TY - JOUR
T1 - Structure-Based Virtual Screening Identifies 2-Arylthiazole-4-Carboxylic Acids as a Novel Class of Nanomolar Affinity Ligands for the CaMKIIα Hub Domain
AU - Tian, Yongsong
AU - Fougiaxis, Vasileios
AU - Sirocchi, Ludovica Stella
AU - Gauger, Stine Juul
AU - Larsen, Anne Sofie Gry
AU - Martino, Elena
AU - Bachmand Chan, Camilla
AU - Bundgaard, Christoffer
AU - Solbak, Sara M Ø
AU - Wellendorph, Petrine
AU - Shehata, Mohamed A
AU - Frølund, Bente
PY - 2025
Y1 - 2025
N2 - The Ca2+/calmodulin-dependent protein kinase II α (CaMKIIα) plays a crucial role in regulating neuronal signaling and higher brain functions, being involved in various brain diseases. Utilization of small molecules targeting the CaMKIIα hub domain has proved to be a promising strategy for specific CaMKIIα modulation and future therapy. Through an in silico structure-based virtual screening campaign, we herein identified 2-arylthiazole-4-carboxylic acids as a new class of high-affinity CaMKIIα hub ligands. Particularly, the 2,6-dichlorophenyl analog, PTCA (compound 1a), displayed mid-nanomolar affinity (pKi = 7.2) and substantial stabilization of the CaMKIIα hub oligomer upon binding. Moreover, the tert-butyl ester prodrug, 14a, was developed to facilitate the brain delivery of PTCA and demonstrated remarkable enhancement in brain penetration compared to PTCA per se after systemic administration. Altogether, our study highlights that PTCA represents a novel and powerful tool compound for future pharmacological interventions targeting CaMKII kinase in the brain.
AB - The Ca2+/calmodulin-dependent protein kinase II α (CaMKIIα) plays a crucial role in regulating neuronal signaling and higher brain functions, being involved in various brain diseases. Utilization of small molecules targeting the CaMKIIα hub domain has proved to be a promising strategy for specific CaMKIIα modulation and future therapy. Through an in silico structure-based virtual screening campaign, we herein identified 2-arylthiazole-4-carboxylic acids as a new class of high-affinity CaMKIIα hub ligands. Particularly, the 2,6-dichlorophenyl analog, PTCA (compound 1a), displayed mid-nanomolar affinity (pKi = 7.2) and substantial stabilization of the CaMKIIα hub oligomer upon binding. Moreover, the tert-butyl ester prodrug, 14a, was developed to facilitate the brain delivery of PTCA and demonstrated remarkable enhancement in brain penetration compared to PTCA per se after systemic administration. Altogether, our study highlights that PTCA represents a novel and powerful tool compound for future pharmacological interventions targeting CaMKII kinase in the brain.
U2 - 10.1021/acs.jmedchem.4c02265
DO - 10.1021/acs.jmedchem.4c02265
M3 - Journal article
C2 - 39874539
SN - 0022-2623
VL - 68
SP - 3031
EP - 3047
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 3
ER -